Events
No Glitches for Biotech in Bangalore
Americans are crying hoarse about being "Bangalored"
in the global information technology (IT) sweepstakes. And IT honchos in
Bangalore are also talking about being "Bangalored" out of Bangalore
due to the intense pressure on the Silicon City´s infrastructure.
|

|
| Karnataka CM Dharam Singh kick starting the
Bangalore Bio 2004 |
|

|
| Kiran Mazumdar-Shaw, Chairperson, Karnataka´s
Vision Group on Biotechnology elaborating the conference objectives |
|

|
| Biotech enthusiasts thronging the stalls in the
exhibition at Palace Grounds |
|

|
| Dr MK Bhan, Secretary, DBT, announcing the
intention to formulate the National Biotech Policy. |
|

|
| MK Shankaralinge Gowda, Secretary to Government,
Dept IT, BT and S&T welcoming the guests to the event |
|

|
| Noted rice breeder, Dr Gurdev S Khush, lighting
the lamp at the inaugural function. |
|

|
| MK Shankaralinge Gowda, Dr Gurdev S Khush, KK
Misra, Korn Thapparansi, Dr MK Bhan, Kiran Mazumdar-Shaw and Jawaid Akhtar
at the inaugural session of Bangalore Bio 2004. |
But the members of the country´s fast growing "biotech
hub", also located in the Garden City can breathe easy. The new,
farmer-friendly Congress-Janata Dal coalition government is all eyes and ears to
tap biotechnology to help their key supporters in rural Karnataka.
This was amply demonstrated at the fourth edition of India´s
largest biotech industry show, Bangalore Bio 2004 in Bangalore from July 11 to
13. Chief Minister Dharam Singh was at hand to launch the event and pep talk the
biotech community. "Our coalition is a pro-poor government. And we will
give top priority to IT and biotechnology," he declared at the inaugural
function. "I am there to help with anything to develop biotechnology in
Karnataka."
His predecessor SM Krishna had announced the state government´s
intention to set up a Biotech Park to provide all the infrastructure facilities
and the ambience required for the growth of the country. And Singh put this
dream on concrete footing by announcing Rs 10 crore outlay to kick off the
biotech park near the Electronic City in South Bangalore. The 100-acre park will
become a reality in a few years. Singh was not averse to tapping the resources
of the world for this venture. He made a specific request to the Central
government to fund an Incubation Center at the proposed biotech park to
stimulate the growth of the industry.
The Bangalore cluster may be growing well on its own. But the
government´s help will come in handy to the budding biotech entrepreneurs.
Bangalore has already become a brand for biotech in the state and the country,
informed the state´s Vision Group on Biotechnology head Kiran Mazumdar-Shaw.
She cited the example of the Bangalore Bio event which has become bigger and
bigger with each edition. This year, it was a record breaker, in spite of the
postponement from the regular mid-April schedule to July due to the
long-stretched national elections.
"Last year saw the entry of 25 new biotech companies in
to the country. Seventeen of them chose to be located in Bangalore," said
Mazumdar-Shaw. There are some 240 registered biotech companies in the country.
At least 110 of them are located in Bangalore. She reeled out other statistics:
$ 8 million in VC investments happened in the city in 2003 and there are over
9000 people working in the city´s biotech sector.
"The biotech industry´s aim is to create a million
jobs by the year 2010. We are on course to achieve this target. The next years
will see fresh investments of Rs 1,000 crore in Karnataka," Mazumdar-Shaw
added.
Praise came from foreign shores too. The German Ambassador to
India Heimo Richter said, "Bangalorebio event has gained excellent
reputation. The German biotech industry is in the consolidation phase and we are
looking towards India to keep the costs down and tap the skill sets available
here." The presence of a large talent pool, institutions like the Indian
Institute of Science and the National Center for Biological Sciences were the
added attractions for German companies", he informed.
Support to Bangalore came from the country´s top biotech
policy maker Dr MK Bhan, secretary, Department of Biotechnology (DBT). "We
should make investments in places which already have a strong presence of
biotech sector to maximize the value. We should concentrate on the states where
all the essential ingredients are already there," he said. He implied that
bioactive cities like Bangalore, Hyderabad, Chennai, Pune, Chandigarh and
Ahmedabad-Vadodara were the ideal places for biotech.
Dr Bhan said the government would soon set up a group of
experts to formulate a National Biotechnology Policy (the need for which was
highlighted by BioSpectrum in its inaugural March 2003 issue itself) and enable
the growing industry to have a secure, favorable environment for growth.
What importance do governments in some other countries do? It
was very clear from a Japanese delegate´s presentation that the country has a
highly evolved national biotechnology strategy. It has four distinct elements,
according to Prof Toru Yao from the Genomic Sciences Center at the TOIN Yokohama
University.
The national biotech strategy envisaged doubling of the
research budgets for this sector in five years and tripling of researchers. The
country also aimed to fuse biotech research with nanotech and IT.
Commercialization of the research developments were being given strong
foundation and the Japanese government planned to make systemic changes to
foster clinical research and initiate deregulation along with fiscal incentives
to spur the growth of the biotech sector.
Ensuring public acceptance of biotech was a key element of
the strategy. This was to be achieved through education, communication and risk
management strategies.
Stiff targets had been set: increase biotech employee numbers
to one million in 2010 from just 30,000 in 2002 and target a 25 times higher
market size in six years. Certainly, Yao said Japan was looking for
collaborations with Indian companies to achieve many of these goals.
The conference had a good number of speakers like the famous
rice breeder, Dr Gurdev Khush, Genomics expert, Samir Brahmachari, DNA
fingerprinting leader Syed Hasnain, bio agri expert, Shanthu Shantharam and a
host of national and international speakers.
The CEO Conclave had a scintillating talk by serial entrepreneur Bala S
Manian on the pitfalls to watch out for during entrepreneurship. There were
plenty of business networking sideshows. The exhibition at the palace grounds
drew a lot of avid biotech enthusiasts on all the three days. Many thronged the
venue braving the heavy monsoon showers. It is time to move on to the next
edition, which may come too soon on schedule in April 2005.
|
Karnataka CM becomes
BioSpectrum subscriber |
|

|
|

BioSpectrum gained an enthusiastic subscriber in Karnataka
Chief Minister Dharam Singh. He inaugurated the exhibition, which was held
as part of the Bangalorebio 2004 and visited almost all the stalls.
When explained about the publishing of Bangalore´s and
South India´s first exclusive national business magazine, BioSpectrum,
devoted to the biotechnology sector, the Chief Minister enthusiastically
become a subscriber of the magazine at the BioSpectrum stall itself. |
|
Biotech Outsourcing
Outsourcing of IT services has become an opportunity for
Indian companies. Can the success story be repeated in biotech too? Yes,
it was possible, argued Julia Llyod-Parks, associate director of
London-based Technomark.
She said typically the big pharma companies were
clearly not in favor of embracing the idea of outsourcing. However, the
mindset has started to change in response to slowing of drug development
time and increasing costs of development. A huge annual market of $ 10
billion existed for outsourcing in the pharma drug development sector.
This sector is growing at 12 percent per year and there are some 1,600
specialized Contract Research Organizations (CROs) worldwide. These are in
the areas of pre-clinical and clinical segments.
The big pharma companies have been looking at using
biotech firms as "surrogate CROs" through alliances. However,
there are very few integrated groups for outsourcing, which have expertise
covering clinical, pharmacology and toxicology sectors.
India is well positioned to take advantage of the opportunities in drug
development. Outsourcing is the mantra, advised Sumanth Venugopal, a
US-based expert. Studies indicate that by 2007 at least 18 to 20 percent
of the drug development work is likely to be outsourced. By 2007, the
global outsourcing market is expected to double to $ 48 billion. |
Page(s) 1 |